Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5629734 | 0.89 | MCL1 (0.44) | RAPGEF4TSHRKDM4EPTPN1CA12 | |
| SCHEMBL28114800 | 0.80 | KDM4E (0.48) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL31335989 | 0.79 | RAPGEF4 (0.49) | RAPGEF4RXRAROCK2PIM1PIM3 | |
| SCHEMBL28025028 | 0.78 | RAPGEF4 (0.48) | RAPGEF4RXRATSHRKDM4EHCAR3 | |
| SCHEMBL29746616 | 0.78 | RAPGEF4 (0.48) | RAPGEF4RXRATSHRKDM4EHCAR3 | |
| SCHEMBL103922 | 0.78 | TUBB4A (0.56) | RAPGEF4RXRAKDM4EHCAR3 | |
| SCHEMBL30233739 | 0.78 | TUBB4A (0.56) | RAPGEF4RXRAKDM4EHCAR3 | |
| SCHEMBL5960506 | 0.78 | RAPGEF4 (0.48) | RAPGEF4RXRAROCK2PIM1PIM3 | |
| SCHEMBL5068315 | 0.75 | TUBB4A (0.57) | RAPGEF4KDM4EPLA2G4APLGPLAU | |
| Hydrazine SCHEMBL1997343 | 0.75 | TUBB4A (0.54) | RAPGEF4RXRAKDM4EHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104854087-B | Indole carboxamide derivatives as P2X receptor antagonists | 埃科特莱茵药品有限公司 | 2017-03-22 | — | — | CN | claimed |
| CN-104854087-A | As P2X7Indole carboxamide derivatives of receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2015-08-19 | — | — | CN | claimed |
| CN-104812749-A | Iindole carboxamide derivatives as p2x7 receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2015-07-29 | — | — | CN | claimed |
| CN-105051037-B | Sphingosine-1-phosphate receptor agonists, method for the preparation thereof and pharmaceutical compositions comprising the same as active agent | LG化学株式会社 | 2018-05-18 | — | — | CN | disclosed |
| CN-107072985-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2017-08-18 | — | — | CN | disclosed |
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | disclosed |
| CN-104854087-B | Indole carboxamide derivatives as P2X receptor antagonists | 埃科特莱茵药品有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | disclosed |
| CN-104812749-B | Indolecarboxamide derivant as P2X7 receptor antagonist | 埃科特莱茵药品有限公司 | 2016-12-14 | — | — | CN | disclosed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | disclosed |
| CN-105051037-A | Sphingosine-1-phosphate receptor agonists, method for the preparation thereof and pharmaceutical compositions comprising the same as active agent | LG LIFE SCIENCES LTD | 2015-11-11 | — | — | CN | disclosed |
| EP-2935211-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-28 | — | — | EP | disclosed |
| CN-104854087-A | As P2X7Indole carboxamide derivatives of receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2015-08-19 | — | — | CN | disclosed |
| CN-104812749-A | Iindole carboxamide derivatives as p2x7 receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2015-07-29 | — | — | CN | disclosed |
| CN-104774205-A | N1/N2-lactam acetyl-coa carboxylase inhibitors | PFIZER | 2015-07-15 | — | — | CN | disclosed |
| CN-103189377-B | N1/n2-lactam acetyl-coa carboxylase inhibitors | PFIZER | 2015-02-25 | — | — | CN | disclosed |
| WO-2014097140-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | RAPGEF4 1859/4885RXRA 737/4885ROCK2 2292/4885 |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | P2RX3, P2RX7, P2RX1 | RAPGEF4 1971/4885RXRA 852/4885ROCK2 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.